Wogonin, 632-85-9,IC-03121464
Product Introduction
Wogonin is a naturally occurring mono-flavonoid originally isolated from the root of Scutellaria baicalensis (Baikal skullcap). It has been demonstrated to inhibit the activity of cyclin-dependent kinase 8 (CDK8) and the Wnt signaling pathway, exhibiting significant anti-inflammatory and anti-tumor effects across multiple cancer cell types. Wogonin induces G1 phase cell cycle arrest and suppresses ¦Â-catenin-mediated transcription through CDK8 inactivation, while also activating peroxisome proliferator-activated receptor gamma (PPAR-¦Ã) to attenuate inflammatory responses. Its dual mechanism of action targeting both oncogenic signaling and inflammatory pathways makes it a valuable tool for investigating cancer biology, inflammation research, and drug discovery applications.
Product Features
1. CDK8 and Wnt Pathway Inhibition: Suppresses CDK8 activity and inhibits Wnt/¦Â-catenin signaling, leading to reduced TCF/Lef-mediated transcription.
2. G1 Cell Cycle Arrest: Induces G0-G1 phase arrest accompanied by downregulation of Cyclin D1 and Cdk4 in multiple cancer cell lines.
3. Anti-Inflammatory Activity: Activates PPAR-¦Ã and attenuates ethanol-induced inflammatory responses in macrophage and liver models.
4. In Vivo Tumor Suppression: Reduces tumor growth in xenograft models and alleviates hepatic injury in alcoholic liver disease models.
5. High Purity Natural Compound: Isolated and purified to ¡Ý98% purity for reliable and reproducible research results.
Specifications
Size: Available in 50 mg, 500 mg, and 1 g
CAS Number: 632-85-9
Purity: 98%
Molecular Weight: 284.26
Molecular Formula: C16H12O5
Solubility: DMSO: 62.5 mg/mL (219.87 mM)
Storage and Stability
Storage Conditions: Store at 2¡ãC to 8¡ãC under inert atmosphere, protected from light.
Shelf Life: The product is stable for 24 months from the date of manufacture when stored as directed.
Protocol (For Reference Only)
Important: Prepare stock solutions freshly and protect from light during handling. Use inert gas when reconstituting for long-term storage.
1. Stock Solution Preparation: Dissolve Wogonin in DMSO to prepare a concentrated stock solution (e.g., 50-200 mM), aliquot into single-use vials, and store at -20¡ãC under inert atmosphere protected from light.
2. In Vitro Working Solution Preparation: Dilute DMSO stock solution into culture medium to achieve desired working concentrations; typical concentrations range from 10-100 µM for cell cycle and proliferation studies.
3. Cell Viability and Proliferation Assays: Treat cells with Wogonin (0-200 µM) for 24-72 hours and assess viability by MTT or CCK-8 assay; dose- and time-dependent effects have been observed in colorectal cancer and cervical carcinoma cell lines.
4. Cell Cycle Analysis: Following Wogonin treatment (10-40 µM for 24-48 hours), harvest cells, fix with 70% ethanol, stain with propidium iodide, and analyze by flow cytometry for G1 phase arrest.
5. Wnt Signaling Analysis: Assess Wnt pathway inhibition by measuring ¦Â-catenin nuclear translocation, TCF/LEF reporter activity, and downstream target gene expression following Wogonin treatment.
Precautions
1. Protect from light and store under inert atmosphere to prevent oxidative degradation of the flavonoid structure.
2. Use appropriate vehicle controls in all experiments; DMSO concentration in culture medium should not exceed 0.1% to avoid solvent-related cytotoxicity.
3. Wogonin may exhibit differential potency across cell lines; optimization of concentration and treatment duration is recommended for specific experimental systems.
4. For in vivo studies, optimize formulation to ensure solubility and bioavailability; co-solvents or suspension agents may be required for oral or intraperitoneal administration.
5. For research use only. Not for use in diagnostic or therapeutic procedures.
FAQ (Simplified)
Q1: What is the recommended starting concentration for in vitro cell cycle arrest studies?
A1: Wogonin at 10-40 µM for 24-48 hours effectively induces G1 arrest in colorectal cancer and cervical carcinoma cells. Higher concentrations (up to 100 µM) may be required for cell lines with lower sensitivity.
Q2: How should I store Wogonin after opening?
A2: Store powder at 2-8¡ãC under inert atmosphere and protected from light. For stock solutions in DMSO, aliquot into single-use volumes and store at -20¡ãC under nitrogen or argon to prevent degradation.
Q3: Does Wogonin affect signaling pathways other than Wnt?
A3: Yes. Wogonin activates PPAR-¦Ã to exert anti-inflammatory effects and modulates additional pathways including NF-¦ÊB. Consider these pleiotropic effects when interpreting experimental results.
Q4: Can Wogonin be used in vivo?
A4: Yes. Intraperitoneal administration of 25-100 mg/kg has been shown to alleviate liver injury in alcoholic liver disease models and reduce tumor growth in xenograft studies. Optimize dosing and vehicle based on specific experimental requirements.
Disclaimer
1. For Research Use Only. Not for use in diagnostic or therapeutic procedures.
2. Due to the variable nature of biological research, optimization of conditions using a small-scale pilot experiment is strongly recommended before processing valuable samples.
3. This warranty is limited to the replacement of the product. The manufacturer assumes no liability for incidental or consequential damages, including loss of samples or data.
4. Wear appropriate protective clothing and gloves when handling this product.
Ordering Information
Catalog Number: IC-03121464
Product Name: Wogonin
Size: 50 mg / 500 mg / 1 g
Price:
50 mg: CNY ¥607.00 / USD $60.70 / EUR €72.84 / JPY ¥10926.00
500 mg: CNY ¥2600.00 / USD $260.00 / EUR €312.00 / JPY ¥46800.00
1 g: CNY ¥4100.00 / USD $410.00 / EUR €492.00 / JPY ¥73800.00
2023 Version
